NCT06323148View on ClinicalTrials.gov

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

226

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2029

Conditions

Lung CancerEGFR Gene MutationMinimal Residual Disease

Interventions

DRUG

Osimertinib

Adjuvant osimertinib for three years after radical surgery

DRUG

No adjuvant therapy

No adjuvant therapy

All Listed Sponsors

lead

Fudan University

OTHER